|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAGLN |
Gene summary for TAGLN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAGLN | Gene ID | 6876 |
| Gene name | transgelin | |
| Gene Alias | SM22 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | Q01995 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6876 | TAGLN | GSM4909281 | Human | Breast | IDC | 2.86e-83 | 1.40e+00 | 0.21 |
| 6876 | TAGLN | GSM4909285 | Human | Breast | IDC | 6.54e-05 | -2.78e-01 | 0.21 |
| 6876 | TAGLN | GSM4909286 | Human | Breast | IDC | 1.57e-03 | -2.52e-01 | 0.1081 |
| 6876 | TAGLN | GSM4909287 | Human | Breast | IDC | 7.15e-03 | 4.07e-01 | 0.2057 |
| 6876 | TAGLN | GSM4909288 | Human | Breast | IDC | 1.44e-02 | 6.24e-01 | 0.0988 |
| 6876 | TAGLN | GSM4909290 | Human | Breast | IDC | 1.10e-03 | -2.90e-01 | 0.2096 |
| 6876 | TAGLN | GSM4909293 | Human | Breast | IDC | 6.88e-04 | -2.52e-01 | 0.1581 |
| 6876 | TAGLN | GSM4909295 | Human | Breast | IDC | 1.34e-06 | 5.93e-01 | 0.0898 |
| 6876 | TAGLN | GSM4909296 | Human | Breast | IDC | 8.93e-04 | -2.36e-01 | 0.1524 |
| 6876 | TAGLN | GSM4909301 | Human | Breast | IDC | 6.13e-05 | -2.85e-01 | 0.1577 |
| 6876 | TAGLN | GSM4909304 | Human | Breast | IDC | 7.39e-05 | -2.72e-01 | 0.1636 |
| 6876 | TAGLN | GSM4909311 | Human | Breast | IDC | 7.63e-04 | -2.41e-01 | 0.1534 |
| 6876 | TAGLN | GSM4909312 | Human | Breast | IDC | 7.67e-04 | -2.74e-01 | 0.1552 |
| 6876 | TAGLN | GSM4909315 | Human | Breast | IDC | 6.16e-03 | -2.84e-01 | 0.21 |
| 6876 | TAGLN | GSM4909319 | Human | Breast | IDC | 3.05e-05 | -2.78e-01 | 0.1563 |
| 6876 | TAGLN | GSM4909321 | Human | Breast | IDC | 5.42e-05 | -2.77e-01 | 0.1559 |
| 6876 | TAGLN | brca3 | Human | Breast | Precancer | 4.40e-13 | 3.70e-01 | -0.0263 |
| 6876 | TAGLN | NCCBC5 | Human | Breast | DCIS | 7.26e-03 | -2.73e-01 | 0.2046 |
| 6876 | TAGLN | P1 | Human | Breast | IDC | 1.13e-02 | -2.49e-01 | 0.1527 |
| 6876 | TAGLN | P2 | Human | Breast | IDC | 4.78e-04 | -2.97e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00075172 | Breast | IDC | muscle organ development | 38/1434 | 327/18723 | 6.63e-03 | 4.62e-02 | 38 |
| GO:00075171 | Breast | DCIS | muscle organ development | 37/1390 | 327/18723 | 6.86e-03 | 4.75e-02 | 37 |
| GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
| GO:000751712 | Endometrium | EEC | muscle organ development | 59/2168 | 327/18723 | 3.49e-04 | 3.85e-03 | 59 |
| GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
| GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
| GO:000751713 | Prostate | Tumor | muscle organ development | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
| GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAGLN | SNV | Missense_Mutation | c.596N>C | p.Ile199Thr | p.I199T | Q01995 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TAGLN | SNV | Missense_Mutation | rs138736412 | c.467N>T | p.Ala156Val | p.A156V | Q01995 | protein_coding | deleterious(0.01) | benign(0.371) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TAGLN | SNV | Missense_Mutation | rs774227686 | c.37N>A | p.Glu13Lys | p.E13K | Q01995 | protein_coding | deleterious(0) | possibly_damaging(0.509) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TAGLN | SNV | Missense_Mutation | rs774227686 | c.37G>A | p.Glu13Lys | p.E13K | Q01995 | protein_coding | deleterious(0) | possibly_damaging(0.509) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TAGLN | SNV | Missense_Mutation | rs746670728 | c.70N>A | p.Glu24Lys | p.E24K | Q01995 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TAGLN | SNV | Missense_Mutation | rs780383343 | c.227C>T | p.Pro76Leu | p.P76L | Q01995 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TAGLN | SNV | Missense_Mutation | rs772350872 | c.580N>A | p.Gly194Arg | p.G194R | Q01995 | protein_coding | deleterious(0.02) | possibly_damaging(0.449) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TAGLN | SNV | Missense_Mutation | rs747524780 | c.584N>A | p.Arg195Gln | p.R195Q | Q01995 | protein_coding | tolerated(0.41) | benign(0.037) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TAGLN | SNV | Missense_Mutation | c.203N>T | p.Ser68Ile | p.S68I | Q01995 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TAGLN | SNV | Missense_Mutation | c.322N>G | p.Lys108Glu | p.K108E | Q01995 | protein_coding | deleterious(0.04) | benign(0.027) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6876 | TAGLN | NA | 5-AZACYTIDINE | AZACITIDINE | 14662021 | |
| 6876 | TAGLN | NA | TGFBETA1 | 16876108 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |